<DOC>
	<DOCNO>NCT01522417</DOCNO>
	<brief_summary>The purpose study ass whether tirofiban regimen high-dose bolus plus shortened infusion duration compare label-dosing eptifibatide patient undergo percutaneous coronary intervention ( PCI ) associate non-inferior composite rate death , PCI-related myocardial infarction , urgent target vessel revascularization in-hospital major bleed within 48 hour follow PCI hospital discharge , whichever come first .</brief_summary>
	<brief_title>Shortened Aggrastat® Versus Integrilin Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Eptifibatide</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<criteria>Age ≥18 year age Scheduled undergo PCI FDA , approve cleared device ( stent procedure balloon angioplasty , rotoblation , AngioSculpt , laser atherectomy , etc . ) one native coronary target lesion Written inform consent Primary PCI STEMI index procedure Prior STEMI within 48 hour randomization Prior PCI within 30 day randomization Planned stag PCI within subsequent 24 hour index PCI Use abciximab within 7 day randomization Use tirofiban eptifibatide within 12 hour randomization Use lowmolecular weight heparin within 12 hour randomization Use bivalirudin within 12 hour randomization</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>